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Object. In many new clinical trials of patients with malignant gliomas surgical intervention is incorporated as an in­
tegral part of tumor-directed interstitial therapies such as gene therapy, biodegradable wafer placement, and immuno­
therapy. Assessment of toxicity is a major component of evaluating these novel therapeutic interventions, but this must 
be done in light of known complication rates of craniotomy for tumor resection. Factors predicting neurological out­
come would also be helpful for patient selection for surgically based clinical trials.
Methods. The Glioma Outcome Project is a prospectively compiled database containing information on 788 patients 
with malignant gliomas that captured clinical practice patterns and patient outcomes. Patients in this series who under­
went their first or second craniotomy were analyzed separately for presenting symptoms, tumor and patient character­
istics, and perioperative complications. Preoperative and intraoperative factors possibly related to neurological out­
come were evaluated.
There were 408 patients who underwent first craniotomies (C1 group) and 91 patients who underwent second ones 
(C2 group). Both groups had similar patient and tumor characteristics except for their median age (55 years in the C1 
group compared with 50 years in the C2 group; p = 0.006). Headache was more common at presentation in the C1 
group, whereas papilledema and an altered level of consciousness were more common at presentation in patients un­
dergoing second surgeries. Perioperative complications occurred in 24% of patients in the C1 group and 33% of pa­
tients in the C2 group (p = 0.1). Most patients were the same or better neurologically after surgery, but more patients 
in the C2 group (18%) displayed a worsened neurological status than those in the C1 group (8%; p = 0.007). The Kar- 
nofsky Performance Scale score and, in patients in the C2 group, tumor size were important neurological outcome 
predictors. Regional complications occurred at similar rates in both groups. Systemic infections occurred more fre­
quently in the C2 group (4.4 compared with 0%; p <  0.0001) as did depression (20 compared with 11%; p = 0.02). 
The perioperative mortality rate was 1.5% for the C1 group and 2.2% for the C2 group (p = not significant). The medi­
an length of the hospital stay was 4 days in each group.
Conclusions. Perioperative complications occur slightly more often following a second craniotomy for malignant 
glioma than after the first craniotomy. This should be considered when evaluating toxicities from intraoperative local 
therapies requiring craniotomy. Nevertheless, most patients are neurologically stable or improved after either their first 
or second craniotomy. This data set may serve as a benchmark for neurosurgeons and others in a discussion of opera­
tive risks in patients with malignant gliomas.
Key W ords • m alignant glioma •
M axim um , safe resection is the primary goal of sur­
gical therapy for malignant glioma.9,24,29 This al­
lows for a definitive diagnosis16 and can improve 
neurological outcome by relieving mass effect and pressure 
on normal brain structures. In many retrospective studies 
researchers have addressed the potential impact of the ex-
Abbreviations used in this paper: GO = Glioma Outcome; KPS = 
Karnofsky Performance Scale; NS = not significant.
craniotom y • postoperative complication • outcome
tent of resection on overall survival in these patients. Most 
have shown prolonged survival in response to more exten­
sive surgery,11,22,29,36 although this remains controversial.10,21 
Perioperative complications after craniotomy and tumor re­
section have been reported in retrospective studies for both 
primary and metastatic brain tumors. Factors affecting mor­
bidity and mortality have been identified. These include pa­
tient characteristics (age, KPS score,18 and medical history), 
tumor characteristics (histological type, location, and size),
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TABLE 1
Characteristics of patients who underwent craniotomy
Characteristic C1 Group C2 Group p Value
male (%) 57 50 0.29
caucasian (%) 86 85 0.88
rt-handed (%) 92 94 0.60
median age (yrs) 55 50 0.006
median KPS score 90 80 0.10
and intraoperative factors (electrophysiological mapping, 
image guidance, and awake procedures) .4-6,8,9,12,24,26,29,30,3234
Once a malignant glioma has recurred after radiation 
therapy, options for further treatment are limited. In select­
ed patients, a repeated operation can be performed.1,3,15,33 
The perioperative complications have been reported to vary 
both in type and severity in this group for a number of rea­
sons. Some authors have suggested that a repeated opera­
tion for malignant glioma is not associated with increased 
risk,27,35 some have shown statistically insignificant trends 
toward increased complications,6,29 and some have suggest­
ed that there clearly is an increased risk.32
Although many surgeons advocate craniotomy for max­
imum tumor resection, data that were prospectively col­
lected on patients with malignant gliomas undergoing cra­
niotomy during the last 5  years have not been reported. 
Recent technical advances including intraoperative electro- 
physiological motor, sensory, and speech mapping, as well 
as interactive image-guidance systems, may have had an 
impact on surgical outcome.4,5,17,24,30,31 The GO Project of­
fered a unique opportunity to collect data prospectively 
from a large number of North American medical centers. 
We sought to describe the medical and neurological com­
plications associated with first and second craniotomies for 
patients with malignant gliomas. This project provides new 
Class II data for neurosurgeons and neurooncologists in­
volved in clinical trials to use as a benchmark for future 
clinical trials that involve surgical interventions.
C linical M a te ria l a n d  M ethods
The GO Project is a prospective longitudinal database, 
initiated in 1 9 9 7 , that tracked clinical practice patterns and 
outcomes among North American patients with malignant 
gliomas. The data were collected from patient and phy­
sician questionnaires, which were completed at 3 -month 
intervals, and were stored at a data coordinating unit estab­
lished at the Center for Outcomes Research at the Univer­
sity of Massachusetts Medical School. The major objective 
of the GO Project was to provide prospectively captured 
benchmark data to enable comparisons among individual 
practice patterns and outcomes.
Fifty-two clinical sites across North America participat­
ed in the GO Project. The enrollment criteria included adult 
patients with primary World Health Organization19 Grade
III or IV gliomas who were undergoing a first or second op­
eration for diagnosis or treatment. Informed consent was 
obtained from all patients included in the database. The data 
collection instruments included questionnaire forms that 
were completed at enrollment, during the perioperative pe­
riod, and at follow-up intervals. Patients were followed pro­
spectively at intervals of 3 months until death or 24 months.
TABLE 2
Preoperative signs and symptoms*
% of Patients
Preop Sign or Symptom C1 Group C2 Group p Value
altered LOC 16 26 0.04
papilledema 4.2 11 0.03
headache 59 46 0.02
memory loss 35 39 0.46
nausea/vomiting 14 10 0.31
motor deficit 32 39 0.18
seizures 31 33 0.64
* LOC = level of consciousness.
Between December 1997 and July 2000, 134 physicians en­
rolled 788 patients at 52 clinical sites. On November 30, 
2001, when patient follow up was concluded, 596 (75.6%) 
of the study patients were known to have died.
The primary outcome measures included treatment, mor­
bidity, and survival. Sociodemographic and related patient 
characteristics were also collected. Physicians recorded 
each patient’s neurological outcome 2 1  days after surgery 
as it compared with their preoperative assessment. This was 
reported as better, same, or worse. Self-reported changes 
in functional capacity, quality of life, and satisfaction with 
care were also captured.
All patients enrolled in the GO Project who underwent 
craniotomy were included in the analysis. Patients who 
underwent a first or second craniotomy were analyzed sep­
arately with respect to presenting symptoms, tumor and pa­
tient characteristics, and perioperative complications. The 
perioperative period was defined as the first 2 1  postopera­
tive days. In univariate analysis, the Student t-test, Wilcox- 
on rank-sum tests, and one-way analysis of variance were 
used for continuous variables, and the chi-square and Fisher 
exact test were used for categorical variables. Logistic re­
gression was used for the multivariate analysis.
R esults
Of the 788 patients enrolled in the GO Project, 408 un­
derwent a first craniotomy (C1 group) and 91 patients un­
derwent a second craniotomy (C2 group). The remaining 
289 patients underwent stereotactic biopsy. The C1 and C2 
groups had similar patient and tumor characteristics, except 
for the median age of the patient (55 years in the C1 group 
compared with 50 years in the C2 group; p = 0.006) (Table 
1). Presenting signs and symptoms for the two groups were 
also similar, except for altered level of consciousness and 
papilledema, which occurred more frequently in the C2 
group, and headache, which was more common in the C1 
group (Table 2). Tumor characteristics for the two groups 
are outlined in Table 3. There were similar distributions of 
tumor size, laterality, and histological grade between the 
two groups. Intraoperative electrophysiological mapping 
was used equally in both groups and the extent of resection 
(biopsy or subtotal and gross-total resections) was also sim­
ilarly distributed between groups. Perioperative complica­
tion rates for the two groups are shown in Table 4. There 
were no significant differences between the two groups 
with respect to perioperative rates of thromboembolic dis­
ease, hemorrhage, seizures, wound infection, or length of
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TABLE 3
Characteristics o f tumors in the two craniotomy groups*
Tumor Characteristic
% of Patients 
C1 Group C2 Group p Value
size (cm) 0.54
< 2 3.3 3.4
2-4 40 42





GBM present 75 67 0.63
cortical mapping performed 22 29 0.17
extent of resection NS
biopsy 1 0
subtotal resection 35 42
gross-total resection 56 54
* GBM = glioblastoma multiforme.
hospital stay when examined individually. The systemic in­
fection rate was higher in the C2 group (4.4 compared with 
0 % in the C1 group; p <  0 .0 0 0 1 ). A worse neurological 
outcome occurred more frequently in this group as well 
(18% in the C2 group compared with 8.1% in the C1 group; 
p = 0.007). There were six perioperative deaths in the C1 
group (1.5%) and two in the C2 group (2.2%; p = NS). De­
pression was noted to be higher in the C2 group (p = 0.02).
To facilitate comparison with other reports in the liter­
ature, complications were categorized as neurological, re­
gional (hemorrhage, wound infection, and seizures), and 
systemic (thromboembolic disease, systemic infection, and 
adverse drug reaction). Among patients in the C1 group, 
postoperatively 53% were neurologically improved, 8.1% 
were neurologically worse, 1 0 % sustained regional com­
plications, and 9.2% sustained systemic complications. In 
this group the overall complication rate was 24.2% and the 
perioperative mortality rate was 1.5%. Among patients in 
the C2 group, 40% were neurologically improved, 18% 
were neurologically worse, 1 3 % sustained regional compli­
cations, and 8.7% sustained systemic complications. In that 
group the overall complication rate was 32.6% and the peri­
operative mortality rate was 2.2%. Differences between 
the C1 and C2 groups were not statistically significant for 
regional complications (p = 0.38), systemic complications 
(p = 0 .8 8 ), or for the overall complication rate (p = 0 .1). 
These data are summarized in Tables 5 and 6 .
A more comprehensive evaluation of the individual cra­
niotomy groups was performed to assess preoperative and 
intraoperative factors that may have been related to neu­
rological outcome. After the first craniotomy, patient age 
and tumor size and location were not significant univariate 
predictors of neurological outcome; however, the patient’s 
KPS score was a significant predictor (p <  0.0001) (Table
7). Multivariate logistic regression showed that the KPS 
score was a significant predictor for “better” or “same” neu­
rological outcome, but not for “worse” outcome (Table
8 ). Among patients who underwent a second craniotomy, 
patient age and tumor location were not significant neuro­
logical outcome predictors, but tumor size (p = 0 .0 2 ) and 
the KPS score (p = 0.003) were (Table 9). A multivariate 




% of Patients 
C1 Group C2 Group p Value
depression 11 20 0.02
deep vein thrombosis 4.2 5.6 0.56
pulmonary embolism 0.5 2.2 0.16
intracranial bleeding 1.6 4.4 0.09
systemic infection 0 4.4 0.0001
seizure 7.5 10.0 0.44
wound infection 0.5 1.1 0.52
adverse drug reaction 5.2 2.2 0.22




median length of hospital stay (days) 4 4 0.86
* Postoperative neurological status compared with preoperative status.
because of the small sample size. Intraoperative electro- 
physiological mapping and the extent of resection did not 
significantly affect neurological outcomes according to ei­
ther univariate analysis or multivariate logistic regression 
analysis for either the C1 or C2 groups.
Discussion
Perioperative complication rates for patients undergoing 
craniotomy for resection of an intraaxial brain tumor have 
been reported previously. Several largely retrospective 
studies spanning the decade prior to initiating the GO Proj­
ect and including patients with both primary and metasta­
tic tumors have been published.5'6'91112'21'293135 We present a 
prospective analysis of perioperative complication rates for 
a large number of patients with malignant gliomas who un­
derwent a first or second craniotomy as part of their thera­
py. Between 1997 and 2000, 134 physicians enrolled 788 
patients at 52 clinical sites in North America. Four hundred 
ninety-nine of these patients underwent craniotomy and are 
included in this analysis. These Class II data on periopera­
tive complications and factors associated with neurological 
outcome in patients undergoing surgery for malignant glio­
mas provides a modern benchmark in this patient group.
Postoperative deterioration in neurological function oc­
curred in 8.1% of patients in the C1 group and 18% of those 
in the C2 group. There was a higher proportion of patients 
in the C2 group who were neurologically worse, despite the 
fact that this group had a younger median age than the C1 
group. It should be noted that the C2 group appeared to 
have a higher proportion of patients with increased intra­
cranial pressure prior to surgery than the C1 group, as evi­
denced by the percentage of patients with an altered level of 
consciousness and papilledema. This may be a contributing 
factor to these patients’ poorer neurological outcomes. Ad­
ditionally, factors that may be associated with neurological 
outcome included KPS score for both patient groups and tu­
mor size in patients who underwent a second craniotomy. 
This is consistent with data from other reports in the litera- 
tUre.4-6'8'9'12'24'26'29'30'32'34 It also emphasizes that patient selec­
tion for surgical clinical trials is an important consideration 
in study design and analysis.
The number of patients who were worse neurological-
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TABLE 5
Published reports of neurological outcomes, regional complications, and systemic complications 
after craniotomy for intraaxial tumor resection*

















Ciric, et al., 1987 1987 Grade II-IV gliomas 42 — 33 7 14 7 — 0
Fadul, et al., 1988 1985-1987 Grade II-IV supratentorial gliomas 213 62 8 26 13.6 8.9 31 3.3
Devaux, et al., 1993 1984-1988 Grade III & IV gliomas 103 — — 20 — — — 0
Kreth, et al., 1993 1986-1991 Grade IV gliomas, patient age 65 yrs 59 — — — 10.5 3.5 — 3.4
Sawaya, et al., 1998 1992-1994 Grade II-IV gliomas, mets 400 61 32 20.75 7 7.75 32 1.7
Vorster & Barnett, 1998 1993-1998 Grade II-IV gliomas, mets, other 224 17 — 19.2 — 12.5 10.6 2.7
Taylor & Bernstein, 1999 1991-1997 Grade II-IV gliomas, mets, other 200 42 — 13 2.5 6 16.5 1
Brell, et al., 2000 1993-1998 Grade II-IV gliomas, mets 200 25 31 20.5 16 4.5 27.5 2.5
Bohinski, et al., 2001 1998-1999 Grade II-IV gliomas 40 21 — 12.5 12.5 5 — 2.5
present study
C1 group 1997-2000 Grade III & IV gliomas 408 0 53 8.1 10 9.2 24.2 1.5
C2 group 1997-2000 Grade III & IV gliomas 91 91 40 18 13 8.7 32.6 2.2
* Comp = complications; mets = metastatic lesions; morbid = morbidity; mortal = mortality; reg = regional; syst = systematic; — = data not given. 
t  Tumor grading based on the World Health Organization classification.
ly after surgery in this series is lower than those cited in 
several other published series. The overall percentage of 
patients who worsened neurologically in both groups was 
9.8%. In seven comparable modern reports of complica­
tions after craniotomy for intraaxial brain tumors, neurolog­
ical deterioration has been reported in 13 to 26% of pa-
tients.5,6,11,12,29,31,35 Only Ciric, et al.,9 have published a lower
rate of neurological worsening (7%), in a study that in­
cluded significant numbers of low-grade gliomas. Possibly, 
this reflects improvements in neurosurgical technique such 
as the incorporation of electrophysiological mapping and 
image guidance. This seems unlikely, however, because 
several of the most recent (and largest) of these studies in­
cluded patients in whom these modalities were used intra- 
operatively.6,29,31,35 It is possible that neurological complica­
tions have been underestimated in the GO Project by using 
2 1  days as a cutoff for perioperative events, instead of the 
more commonly used 30-day time period.6,29,31,35 Given that
neurological deficits seldom present late after craniotomy, 
however, this also seems unlikely. Authors of some studies 
have suggested that tumor location in eloquent cortex is a 
predictive factor for worse neurological outcome,29,31,35 al­
though this finding has not been universal.6 Whether the site 
of the operation was in an eloquent or noneloquent location 
was not recorded in the GO Project, and it is possible that 
this series contains a smaller proportion of patients with tu­
mors in eloquent locations. This seems particularly plaus­
ible because the GO Project reflects community practice 
patterns, whereas other reported series reflect the experi­
ence of specialized referral centers, where surgeons may be 
more inclined to attempt resection of lesions in eloquent 
cortex. Additionally, a selection bias toward better surgical 
candidates by referring neurosurgeons may have contribut­
ed in part to lower neurological complication rates.
There was a trend toward a moderately increased risk for 
regional complications with second craniotomy (1 0 % in the
TABLE 6
Published reports of neurological outcomes, regional complications, and systemic complications 
after second craniotomy fo r  malignant glioma
















Young, et al., 1981 1966-1974 supratentorial Grade 
III & IV gliomas
24 25 54 25 — — 16.7
Salcman, et al., 1982 1978-1981 Grade III & IV gliomas 60 — — 8.3 — — 0
Ammirati, et al., 1987 1972-1983 Grade III & IV gliomas 55 45 25 14.5 5.5 16 1.4
Harsh, et al., 1987 1975-1984 Grade III & IV gliomas 70 7.1 7.1 — — — 4.3
Vick, et al., 1989 1989 Grade III & IV gliomas 15 — 0 0 0 0 0
Landy, et al., 1994 1994 Grade III & IV gliomas 33 33 2.1 — — — 0
Barker, et al., 1998 1988-1993 Grade IV gliomas 46 28 23 — — — 0
present study, C2 group 1997-2000 Grade III & IV gliomas 91 40 18 13 8.7 32.6 2.2
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TABLE 7
Results o f univariate analysis o f preoperative factors 
that may be associated with neurological outcome 
in patients undergoing first craniotomy
Postop Neurological Status
Factor Worse Same Better p Value
mean age of patient (yrs) 55.6 53.1 53.9 0.72
mean KPS score 82.4 88.3 78.0 0.0001
tumor size (cm)* 0.13
< 2  (13 patients) 15.9 53.9 30.8
2-4 (155 patients) 10.3 41.9 47.7
> 4  (216 patients) 6.0 36.6 57.4
tumor laterality* 0.88
lt (193 patients) 7.3 38.3 54.4
rt (177 patients) 9.6 38.4 51.9
midline (2 patients) 0.0 50.0 50.0
bilat (10 patients) 10.0 50.0 40.0
* Values represent percentages of patients.
C1 group and 13% in the C2 group), but this was not sta­
tistically significant (p = 0.38). These rates for regional 
complications are similar to those of previous studies (2.5­
16% of patients undergoing craniotomy for intraaxial brain 
tumors; Table 5 ) .5.6.9.12.21.29.31 Interestingly, there was no sig­
nificant difference in wound infections between the C1 and 
C2 groups (0.5 compared with 1.1%, respectively; p = 
0.52). The systemic infection rate was increased in the C2  
group (0% in the C1 group and 4.4% in the C2 group; p <  
0 .0 0 0 1 ), but the overall systemic complication was not 
(9.2% in the C1 group and 8.7% in the C2 group; p = 0.88). 
It is possible that this reflects prolonged use of corticoste­
roid medication or previous chemotherapy in patients in the 
C2  group compared with those in the C1 group. These sys­
temic complication rates are similar to those cited in pre­
viously published series (3.5-12.5%; Table 5 ) .5.6.9.12.21.29.31,35 
The perioperative mortality rate in patients in the C1 group 
was 1.5% and that in patients in the C2 group was 2.2% in 
C2 (p = NS). This is similar to rates published for previous 
series (1-3.4%; Table 5) .5'6'9'12'2129'31'35
Depression was also recorded in the GO Project. Al­
though the existence of depression in patients with brain 
tumor has been described previously,2 it has not been sys­
tematically recorded in an intraaxial tumor surgical se-
ries.5,6,9,12,21,29,31,35 The overall incidence of physician-report­
ed depression in this series was 13%, but this rate differed 
significantly between the C1 and C2 groups (11 compared 
with 20%, respectively; p = 0.02). It is possible that this 
increase reflects both local alterations in neurophysiological 
characteristics secondary to brain tumor invasion and a nor­
mal psychological reaction to tumor progression. In any 
event, these data provide important insight into the quality 
of life of a patient harboring a malignant glioma. The rela­
tively high depression rate in this series should alert physi­
cians to the possibility that patients with brain tumors may 
be suffering from this treatable disorder.
Increasingly, tumor-directed therapies, such as chemo­
therapy wafers, gene therapy, brachytherapy, and conjugat­
ed toxin therapy, are being developed that require a crani­
otomy as part of the treatment plan.7,13,14,20,25 Neurosurgeons 
and neurooncologists need to be aware of the incidence of 
complications from craniotomy alone so they can put the
TABLE 8
Results o f multivariate analysis o f preoperative factors that may 
be associated with neurological outcome in patients 
undergoing first craniotomy
95% Confidence
Preop Factor Odds Ratio Interval p Value
factors for worse outcome
patient age 1.018 0.987-1.051 0.26
KPS score 1.029 0.989-1.069 0.15
tumor size 2 cm 2.236 0.243-20.58 0.48
tumor size 2-4 cm 1.523 0.604-3.842 0.37
tumor location: rt side 0.809 0.329-1.988 0.64
factors for same outcome
patient age 1.004 0.987-1.022 0.63
KPS score 1.061 1.036-1.087 0.0001
tumor size 2 cm 1.603 0.585-11.585 0.21
tumor size 2-4 cm 1.016 0.600-1.720 0.95
tumor location: rt side 1.066 0.635-1.789 0.81
factors for better outcome
patient age 0.990 0.972-1.008 0.27
KPS score 0.938 0.916-0.960 0.0001
tumor size 2 cm 0.272 0.052-1.438 0.12
tumor size 2-4 cm 0.858 0.509-1.444 0.56
tumor location: rt side 1.005 0.601-1.681 0.98
safety of these new therapies in context. This is particular­
ly true for repeated craniotomies, in which the risk of com­
plication may be higher than that for the initial surgery. The 
data from the GO Project presented here are particularly 
helpful in defining the risks of repeated craniotomy com­
pared with those of first craniotomy for malignant gliomas. 
These data indicate a modest, but acceptable trend toward 
increased perioperative complications among patients un­
dergoing second craniotomy (24.2% in the C1 group and 
32.6% in the C2 group; p = 0.1). The majority (82%) of pa­
tients were the same or improved neurologically after sur­
gery. Relatively few reports of patients undergoing repeat­
ed craniotomy for malignant glioma have been published 
previously. Seven series from the last two decades, in which 
patients were accrued between 1966 and 1993, are summa­
rized in Table 6 .1A15'23'283337 These largely retrospective stud-
TABLE 9
Results o f univariate analysis o f preoperative factors 
that may be associated with neurological outcome 
in patients undergoing second craniotomy
Neurological Status
Factor Worse Same Better p Value
mean age of patients (yrs) 51.0 48.7 49.9 0.89
mean KPS score 75.3 86.3 72.0 0.003
tumor size (cm)* 0.02
2 (3 patients) 33.3 33.3 33.3
2-4 (35 patients) 22.9 57.1 20.0
4 (47 patients) 12.8 34.0 53.2
tumor laterality* 0.72
lt (48 patients) 14.6 43.8 41.7
rt (34 patients) 20.6 38.2 41.2
midline (2 patients) 50.0 50.0 0.0
bilat (3 patients) 33.3 33.3 33.3
* Values represent percentages of patients.
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ies, ranging in size between 15 and 70 patients each, are not 
always consistent with each other with respect to record­
ing complications and are heterogeneous in their results (for 
example, there is a range of neurological worsening of 
0-54% );33,37 this makes a direct comparison with the present 
series difficult. In general, the prospective data obtained 
from the 91 patients enrolled in the GO Project who under­
went second craniotomies compares well with data pub­
lished in these reports, and represents a more comprehen­
sive and less biased evaluation of perioperative outcome in 
this patient population.
Although the GO Project provides significant informa­
tion about the patterns of care and neurosurgical outcomes 
for a large group of patients with malignant gliomas, there 
are limitations. Patient selection in this study was probably 
skewed toward the “best” patients in factors such as KPS 
score and, hence, in outcomes. Although attempts were 
made at contributing institutions to enroll consecutive pa­
tients, this was not performed over a specific time period 
and was often impossible due to logistical and other rea­
sons. This may have allowed for selection bias. Also, the 
centers at which these patients enrolled were self-selected 
for an interest in surgical management of malignant glio­
mas and may not reflect universal practice patterns. Never­
theless, the project was not limited to academic institutions 
and we believe that it reflects a community experience with 
craniotomy for patients with gliomas. In addition, in this 
study examined complications occurring within the first 21  
days postoperatively. As a result it is possible that compli­
cation rates have been underestimated in this study. In most 
other series the researchers have defined perioperative com­
plications as those occurring within the first 30 days after 
surgery.6293135 Despite these limitations, our results proba­
bly represent some of the best population-based data for the 
modern era on which to base a discussion of the periopera­
tive complications facing patients with malignant gliomas.
C onclusions
We present perioperative complications of first and sec­
ond craniotomy among 499 patients undergoing open sur­
gery enrolled in the GO Project. Rates of wound infection, 
seizures, thromboembolic disease, hemorrhage, and length 
of hospital stay were similar among patients in the C1 and 
C2 groups, but systemic infection and depression occurred 
more frequently in those in the C2 group. Furthermore, neu­
rological outcome was worse for patients undergoing sec­
ond craniotomy. The KPS score was an important predictor 
of neurological outcome among both groups. For patients 
who underwent a second craniotomy, tumor size was also 
predictive. Nevertheless, the increased risk associated with 
second craniotomy for malignant glioma is modest and 
most patients were neurologically unchanged or improved 
postoperatively. Investigators studying experimental thera­
pies involving craniotomy for the intratumoral or interstitial 
administration of novel agents to patients with newly diag­
nosed or recurrent malignant glioma should consider these 
results when evaluating the toxicity of these treatments.
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